CAJ | 학술논문

目的：观察吉西他滨联合紫杉醇（GT）及卡培他滨联合多西他赛（XT）方案治疗复发转移性乳腺癌的临床疗效及毒副反应。方法：复发转移性乳腺癌患者36例，采用回顾性研究方法分为两组：GT 组18人，第1天紫杉醇175mg/ m2静滴3小时，第1、8天吉西他滨1000mg/ m2静滴30分钟，21天为一周期；XT 组18人，第1天多西他赛75mg/ m2静滴1小时，第1～14天卡培他滨1000mg/ m2口服 Bid，周期同为21天。化疗期间观察患者化疗毒副反应，每两周期行影像学检查评价疗效。结果：GT 组 CR 为11.1％，PR 为38.9％，SD 为27.8％，DCR 为77.8％；XT 组 CR 为5.6％，PR 为44.4％，SD 为22.2％，DCR 为72.2％，两组对比无统计学差异（P ＞0.05）。GT 组中位 TTP 为8.7个月，XT 组中位 TTP 为7.8个月，两者统计学上无差异（P ＞0.05）。毒副反应方面 GT 组血小板减少发生率较 XT 组高，XT 组手足综合征发生率高于 GT 组，其余各项无显著性差异（P ＞0.05）。结论：GT 方案与 XT 方案治疗复发转移性乳腺癌疗效确切，毒副反应能耐受。
목적：관찰길서타빈연합자삼순（GT）급잡배타빈연합다서타새（XT）방안치료복발전이성유선암적림상료효급독부반응。방법：복발전이성유선암환자36례，채용회고성연구방법분위량조：GT 조18인，제1천자삼순175mg/ m2정적3소시，제1、8천길서타빈1000mg/ m2정적30분종，21천위일주기；XT 조18인，제1천다서타새75mg/ m2정적1소시，제1～14천잡배타빈1000mg/ m2구복 Bid，주기동위21천。화료기간관찰환자화료독부반응，매량주기행영상학검사평개료효。결과：GT 조 CR 위11.1％，PR 위38.9％，SD 위27.8％，DCR 위77.8％；XT 조 CR 위5.6％，PR 위44.4％，SD 위22.2％，DCR 위72.2％，량조대비무통계학차이（P ＞0.05）。GT 조중위 TTP 위8.7개월，XT 조중위 TTP 위7.8개월，량자통계학상무차이（P ＞0.05）。독부반응방면 GT 조혈소판감소발생솔교 XT 조고，XT 조수족종합정발생솔고우 GT 조，기여각항무현저성차이（P ＞0.05）。결론：GT 방안여 XT 방안치료복발전이성유선암료효학절，독부반응능내수。
Objective:To study the clinical curative effect and adverse of gemcitabine plus taxol(GT)and xeloda plus docetaxel(XT)in recurrent and metastatic breast cancer. Methods:Using retrospective study,36 cases of recur-rent and metastatic breast cancer were divided into two groups. The 18 patients in the GT group received the GT chemotherapy regimen(taxol 175mg/ m2 on the 1st day;gemcitabine 1 000mg/ m2 on the 1st day and 8th day;and 21 days for a cycle. The 18 patients in the XT group received the chemotherapy regimen:docetaxel 75mg/ m2 on the 1st day;Capecitabine orally 2 000mg/(m2 ·d),twice a day from the 1st day to 14th day;and 21 days for a cycle. Re-sults:In GT group,2 patients achieved complete response( CR),7 patients achieved partial remission( PR),5 patients achieved stable disease( SD),and the response rate was about 77. 8% . In XT group,1 patient achieved complete response(CR),8 patients achieved partial remission(PR),4 patients achieved stable disease(SD),and the response rate was 72. 2% . There was no statistically significant differrence between two groups(P > 0. 05). The median TTP of GT group was 8. 7 months,while XT group median TTP was 7. 8 months,without any difference statisti-cally. There was higher incidence of thrombocytopenia in GT group than XT group,and incidence of extremities syn-drome in XT group was higher than GT group. Conclusion:The curative effect of GT and XT regimens in treating re-current and metastatic breast cancer is obvious and the toxicities can be tolerated.